Phase 1 Study of Aflibercept Administered Subcutaneously to Patients with Advanced Solid Tumors - Concepedia

Concepedia

Publication | Open Access

Phase 1 Study of Aflibercept Administered Subcutaneously to Patients with Advanced Solid Tumors

DOI Full Paper Access

88

Citations

17

References

2009

Year

William P. Tew, Michael S. Gordon, John R. Murren, Jakob Dupont, S. Pezzulli, Carol Aghajanian, Paul Sabbatini, David S. Mendelson, Lawrence Schwartz, Scott Gettinger,

Clinical Cancer Research

Abstract

Subcutaneous aflibercept was well tolerated and had manageable side effects. Its favorable pharmacokinetic profile and potential antitumor activity warrants further evaluation.

References

	Year	Citations

Page 1